TICKERNOMICS Sign up
Last Update: 2024-03-28 02:15:22
Acer Therapeutics Inc. ( ACER ) https://www.acertx.com
0.80USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
ACER
7.27%
SPY
32.74%
-73.00%
ACER
SPY
92.93%
-96.69%
ACER
SPY
224.41%
-99.48%
ACER
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
19.68
-594639.14
0.05
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.39
0.00
-0.41
-113.08
0.00
24189.80
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-0.00
77.46
-0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.0977
2476965.65
187.33
0.49
Other Earnings and Cash Flow Stats:
Acer Therapeutics Inc. ( ACER ) Net Income TTM ($MM) is -47.24
Acer Therapeutics Inc. ( ACER ) Operating Income TTM ($MM) is -17.96
Acer Therapeutics Inc. ( ACER ) Owners' Earnings Annual ($MM) is -32.05
Acer Therapeutics Inc. ( ACER ) Current Price to Owners' Earnings ratio is -0.61
Acer Therapeutics Inc. ( ACER ) EBITDA TTM ($MM) is -18.24
Acer Therapeutics Inc. ( ACER ) EBITDA Margin is -0.00%
Capital Allocation:
Acer Therapeutics Inc. ( ACER ) has paid 0.00 dividends per share and bought back -8.696574 million shares in the past 12 months
Acer Therapeutics Inc. ( ACER ) has reduced its debt by 14.111863 million USD in the last 12 months
Capital Structure:
Acer Therapeutics Inc. ( ACER ) Interest-bearing Debt ($MM) as of last quarter is 0
Acer Therapeutics Inc. ( ACER ) Annual Working Capital Investments ($MM) are -868251
Acer Therapeutics Inc. ( ACER ) Book Value ($MM) as of last quarter is -48
Acer Therapeutics Inc. ( ACER ) Debt/Capital as of last quarter is -1%
Other Balance Sheet Stats:
Acer Therapeutics Inc. ( ACER ) has 594659 million in cash on hand as of last quarter
Acer Therapeutics Inc. ( ACER ) has 61 million of liabilities due within 12 months, and long term debt 32 as of last quarter
Acer Therapeutics Inc. ( ACER ) has 24 common shares outstanding as of last quarter
Acer Therapeutics Inc. ( ACER ) has 0 million USD of preferred stock value
Academic Scores:
Acer Therapeutics Inc. ( ACER ) Altman Z-Score is 632458.86 as of last quarter
Acer Therapeutics Inc. ( ACER ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Acer Therapeutics Inc. ( ACER ) largest shareholder is BlackRock Inc owning 76772 shares at 0.06 ($MM) value
Chris Schelling(an insider) Bought 819672 shares of Acer Therapeutics Inc. ( ACER ) for the amount of $999999.84 on 2022-11-29
13.78% of Acer Therapeutics Inc. ( ACER ) is held by insiders, and 29.91% is held by institutions
Acer Therapeutics Inc. ( ACER ) went public on 2017-09-22
Other Acer Therapeutics Inc. ( ACER ) financial metrics:
FCF:-32.89
Unlevered Free Cash Flow:868212.22
EPS:-2.41
Operating Margin:-0.00
Gross Profit Margin:77.46
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:123.42
Beta:0.49
Buffet's Owners Earnings:-32.05
Price to Owner's Earnings:-0.61
About Acer Therapeutics Inc. ( ACER ) :
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.